208 related articles for article (PubMed ID: 22088956)
1. Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis.
Bakal RL; Gattani SG
Eur J Med Chem; 2012 Jan; 47(1):278-82. PubMed ID: 22088956
[TBL] [Abstract][Full Text] [Related]
2. Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.
Mahajan NS; Dhawale SC
Eur J Med Chem; 2015 Sep; 102():243-8. PubMed ID: 26280920
[TBL] [Abstract][Full Text] [Related]
3. Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R; Schecter GF; Flood J; Porco TC
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
[TBL] [Abstract][Full Text] [Related]
4. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.
Lai CC; Tan CK; Huang YT; Chou CH; Hung CC; Yang PC; Luh KT; Hsueh PR
Clin Infect Dis; 2008 Oct; 47(7):e57-63. PubMed ID: 18715157
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
6. Extensively drug-resistant tuberculosis: epidemiology and management challenges.
Dheda K; Warren RM; Zumla A; Grobusch MP
Infect Dis Clin North Am; 2010 Sep; 24(3):705-25. PubMed ID: 20674800
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
8. Extensively drug-resistant (XDR) tuberculosis: an old and new threat.
Fattorini L; Migliori GB; Cassone A
Ann Ist Super Sanita; 2007; 43(4):317-9. PubMed ID: 18209265
[TBL] [Abstract][Full Text] [Related]
9. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
[TBL] [Abstract][Full Text] [Related]
10. Extensively drug-resistant tuberculosis in california, 1993-2006.
Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
[TBL] [Abstract][Full Text] [Related]
11. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB.
Martins M; Viveiros M; Couto I; Amaral L
Int J Tuberc Lung Dis; 2009 May; 13(5):569-73. PubMed ID: 19383188
[TBL] [Abstract][Full Text] [Related]
12. Drug susceptibility profile of Mycobacterium tuberculosis isolated from HIV infected and uninfected pulmonary tuberculosis patients in eastern India.
Chakraborty N; De C; Bhattacharyya S; Mukherjee A; Santra S; Banerjee D; Sarkar RN; Guha SK
Trans R Soc Trop Med Hyg; 2010 Mar; 104(3):195-201. PubMed ID: 19828165
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
14. Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control.
Migliori GB; D'Arcy Richardson M; Sotgiu G; Lange C
Clin Chest Med; 2009 Dec; 30(4):637-65, vii. PubMed ID: 19925959
[TBL] [Abstract][Full Text] [Related]
15. New tuberculosis drugs on the horizon.
Cole ST; Riccardi G
Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
[TBL] [Abstract][Full Text] [Related]
16. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting.
Vella V; Racalbuto V; Guerra R; Marra C; Moll A; Mhlanga Z; Maluleke M; Mhlope H; Margot B; Friedland G; Shah NS; Gandhi NR
Int J Tuberc Lung Dis; 2011 Sep; 15(9):1170-5, i. PubMed ID: 21943840
[TBL] [Abstract][Full Text] [Related]
17. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.
Sun Z; Zhang J; Song H; Zhang X; Li Y; Tian M; Liu Y; Zhao Y; Li C
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1436-41, i. PubMed ID: 20937184
[TBL] [Abstract][Full Text] [Related]
18. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J
Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia.
Punga VV; Jakubowiak WM; Danilova ID; Somova TR; Volchenkov GV; Kazionnyy BY; Nemtsova ES; Kiryanova EV; Kourbatova EV
Int J Tuberc Lung Dis; 2009 Oct; 13(10):1309-12. PubMed ID: 19793439
[TBL] [Abstract][Full Text] [Related]
20. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.
Tabarsi P; Chitsaz E; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Amiri M; Mansouri D; Masjedi MR; Velayati AA; Caminero JA
Microb Drug Resist; 2010 Mar; 16(1):81-6. PubMed ID: 20192820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
